



Press Release

FOR IMMEDIATE RELEASE

CRITICAL OUTCOME TECHNOLOGIES INC. ENGAGES LIFE SCIENCE EXECUTIVE

London, Ontario (June 21, 2011): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that it has entered into a consulting agreement with Dr. Brent Norton, MBA, ICD.D, a member of its Board of Directors, under an Executive Management Consulting services agreement. In his role as Executive Director, Dr. Norton will assist the Company in a broad range of areas including: licensing strategy, collaboration development, new revenue stream development, financing and investor relations strategies and corporate governance.

“Dr. Norton is an accomplished executive in the Life Science industry with significant leadership and licensing experience as a Founder, President, CEO and Director of several successful Life Science companies,” said Dr. Wayne Danter, President and CEO of COTI. “We look forward to working with him and utilizing his considerable skill set in a number of important areas of the Company.”

The Compensation Committee of the Board of Directors approved the granting of 200,000 stock options to Dr. Norton under the Company’s Stock Option Plan at its meeting of June 21, 2011 as part of the compensation for services to be provided to COTI’s management team. The options have a five year life with 50,000 options vesting on each of the following dates: September 1 and December 1, 2011 and March 1 and June 1, 2012. The exercise price is \$0.35 and represents the closing price of the Company’s common shares on Monday, June 20, 2011, the last trade reported on the TSX Venture Exchange prior to the meeting date.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge biotechnology firm specialized in assisting pharmaceutical, biotechnology and therapeutic companies with the accelerated discovery of small molecules to enable new drugs to be brought to market in a cost effective, efficient and timelier manner.

COTI’s proprietary technology CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, please visit www.criticaloutcome.com or contact:

Gene Kelly
Chief Financial Officer
519-858-5157
gkelly@criticaloutcome.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.